Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 508-522

  Phoenix, Timothy N ^a   Patmore, Deanna M ^b   Boop, Scott ^a   Boulos, Nidal ^a   Jacus, Megan O ^a   Patel, Yogesh T ^a   Roussel, Martine F ^a   Finkelstein, David ^a   Goumnerova, Liliana ^c   Perreault, Sebastien ^d   Wadhwa, Elizabeth ^c   Cho, Yoon Jae ^d   Stewart, Clinton F ^a   Gilbertson, Richard J ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CISPLATIN; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CONDITIONED MEDIUM; GLUCOSE TRANSPORTER 1; HYBRID PROTEIN; MEMBRANE PROTEIN; PLVAP PROTEIN, HUMAN; SLC2A1 PROTEIN, HUMAN; TUMOR PROTEIN; WNT PROTEIN; WNT7A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; IN VIVO STUDY; MEDIAN SURVIVAL TIME; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION; WNT SIGNALING PATHWAY; ANIMAL; CEREBELLAR NEOPLASMS; CLASSIFICATION; CONDITIONED MEDIUM; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE VECTOR; GENETIC ASSOCIATION STUDY; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOLOGY; PERICYTE; PHARMACOLOGY; PHYSIOLOGY; SECRETION (PROCESS); THERAPEUTIC USE; TIGHT JUNCTION; TRANSGENIC MOUSE; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CARRIER PROTEINS; CEREBELLAR NEOPLASMS; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; GENETIC ASSOCIATION STUDIES; GENETIC VECTORS; GENOTYPE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MEDULLOBLASTOMA; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; PARACRINE COMMUNICATION; PERICYTES; RECOMBINANT FUSION PROTEINS; TIGHT JUNCTIONS; TRANSDUCTION, GENETIC; VINCRISTINE; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84962094334     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.002     Document Type: Article

References (55)

1. Alvarez J.I., Dodelet-Devillers A., Kebir H., Ifergan I., Fabre P.J., Terouz S., Sabbagh M., Wosik K., Bourbonniere L., Bernard M., et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011, 334:1727-1731.
2. Armulik A., Genove G., Mae M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., et al. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
3. Atkinson J.M., Shelat A.A., Carcaboso A.M., Kranenburg T.A., Arnold L.A., Boulos N., Wright K., Johnson R.A., Poppleton H., Mohankumar K.M., et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011, 20:384-399.
4. Avula S., Mallucci C., Kumar R., Pizer B. Posterior fossa syndrome following brain tumour resection: review of pathophysiology and a new hypothesis on its pathogenesis. Childs Nerv. Syst. 2015, 31:1859-1867.
5. Biechele T.L., Adams A.M., Moon R.T. Transcription-based reporters of Wnt/beta-catenin signaling. Cold Spring Harb Protoc. 2009, 2009. pdb.prot5223.
6. Bolton S.J., Anthony D.C., Perry V.H. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 1998, 86:1245-1257.
7. Boyle F.M., Eller S.L., Grossman S.A. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol. 2004, 6:300-305.
8. Chang D.K., Grimmond S.M., Evans T.R., Biankin A.V. Mining the genomes of exceptional responders. Nat. Rev. Cancer 2014, 14:291-292.
9. Corada M., Nyqvist D., Orsenigo F., Caprini A., Giampietro C., Taketo M.M., Iruela-Arispe M.L., Adams R.H., Dejana E. The Wnt/β-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev. Cell 2010, 18:938-949.
10. Daneman R., Agalliu D., Zhou L., Kuhnert F., Kuo C.J., Barres B.A. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc. Natl. Acad. Sci. USA 2009, 106:641-646.
11. Daneman R., Zhou L., Agalliu D., Cahoy J.D., Kaushal A., Barres B.A. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One 2010, 5:e13741.
12. Daneman R., Zhou L., Kebede A.A., Barres B.A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010, 468:562-566.
13. Ellison D.W., Onilude O.E., Lindsey J.C., Lusher M.E., Weston C.L., Taylor R.E., Pearson A.D., Clifford S.C. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J. Clin. Oncol. 2005, 23:7951-7957.
14. Firth J.A. Endothelial barriers: from hypothetical pores to membrane proteins. J. Anat. 2002, 200:541-548.
15. Gajjar A.J., Robinson G.W. Medulloblastoma-translating discoveries from the bench to the bedside. Nat. Rev. Clin. Oncol. 2014, 11:714-722.
16. Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L.E., Merchant T.E., Woo S., Wheeler G., Ahern V., Krasin M.J., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006, 7:813-820.
17. Gibson P., Tong Y., Robinson G., Thompson M.C., Currle D.S., Eden C., Kranenburg T.A., Hogg T., Poppleton H., Martin J., et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010, 468:1095-1099.
18. Goodrich L.V., Milenkovic L., Higgins K.M., Scott M.P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277:1109-1113.
19. Iyer G., Hanrahan A.J., Milowsky M.I., Al-Ahmadie H., Scott S.N., Janakiraman M., Pirun M., Sander C., Socci N.D., Ostrovnaya I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
20. Jain R.K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014, 26:605-622.
21. Jones D.T.W., Jager N., Kool M., Zichner T., Hutter B., Sultan M., Cho Y.-J., Pugh T.J., Hovestadt V., Stutz A.M., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
22. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354.
23. Kahn M. Can we safely target the WNT pathway?. Nat. Rev. Drug Discov. 2014, 13:513-532.
24. Kawauchi D., Robinson G., Uziel T., Gibson P., Rehg J., Gao C., Finkelstein D., Qu C., Pounds S., Ellison D.W., et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012, 21:168-180.
25. Kool M., Jones D.T., Jager N., Northcott P.A., Pugh T.J., Hovestadt V., Piro R.M., Esparza L.A., Markant S.L., Remke M., et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014, 25:393-405.
26. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:781-810.
27. Marx V. Cancer: a most exceptional response. Nature 2015, 520:389-393.
28. Mohankumar K.M., Currle D.S., White E., Boulos N., Dapper J., Eden C., Nimmervoll B., Thiruvenkatam R., Connelly M., Kranenburg T.A., et al. An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. Nat. Genet. 2015, 47:878-887.
29. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., Hall W.A., Hynynen K., Senter P.D., Peereboom D.M., Neuwelt E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 2007, 25:2295-2305.
30. Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 2011, 29:1408-1414.
31. Northcott P.A., Jones D.T.W., Kool M., Robinson G.W., Gilbertson R.J., Cho Y.-J., Pomeroy S.L., Korshunov A., Lichter P., Taylor M.D., Pfister S.M. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 2012, 12:818-834.
32. Northcott P.A., Shih D.J.H., Peacock J., Garzia L., Sorana Morrissy A., Zichner T., Stutz A.M., Korshunov A., Reimand J., Schumacher S.E., et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012, 488:49-56.
33. Oliver T.G., Read T.A., Kessler J.D., Mehmeti A., Wells J.F., Huynh T.T., Lin S.M., Wechsler-Reya R.J. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005, 132:2425-2439.
34. Parrish K.E., Sarkaria J.N., Elmquist W.F. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin. Pharmacol. Ther. 2015, 97:336-346.
35. Perreault S., Ramaswamy V., Achrol A.S., Chao K., Liu T.T., Shih D., Remke M., Schubert S., Bouffet E., Fisher P.G., et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am. J. Neuroradiol. 2014, 35:1263-1269.
36. Pugh T.J., Weeraratne S.D., Archer T.C., Pomeranz Krummel D.A., Auclair D., Bochicchio J., Carneiro M.O., Carter S.L., Cibulskis K., Erlich R.L., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012, 488:106-110.
37. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., Olson O.C., Quick M.L., Huse J.T., Teijeiro V., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
38. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
39. Reis M., Czupalla C.J., Ziegler N., Devraj K., Zinke J., Seidel S., Heck R., Thom S., Macas J., Bockamp E., et al. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J. Exp. Med. 2012, 209:1611-1627.
40. Roberts K.G., Mullighan C.G. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat. Rev. Clin. Oncol. 2015, 12:344-357.
41. Robinson G., Parker M., Kranenburg T.A., Lu C., Chen X., Ding L., Phoenix T.N., Hedlund E., Wei L., Zhu X., et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012, 488:43-48.
42. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
43. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S.-i., Watanabe H., Kurashina K., Hatanaka H., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
44. Solomon B.J., Mok T., Kim D.-W., Wu Y.-L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371:2167-2177.
45. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic [bgr]-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
46. Stenman J.M., Rajagopal J., Carroll T.J., Ishibashi M., McMahon J., McMahon A.P. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 2008, 322:1247-1250.
47. Thompson M.C., Fuller C., Hogg T.L., Dalton J., Finkelstein D., Lau C.C., Chintagumpala M., Adesina A., Ashley D.M., Kellie S.J., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 2006, 24:1924-1931.
48. Uziel T., Zindy F., Xie S., Lee Y., Forget A., Magdaleno S., Rehg J.E., Calabrese C., Solecki D., Eberhart C.G., et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 2005, 19:2656-2667.
49. Vallon M., Chang J., Zhang H., Kuo C.J. Developmental and pathological angiogenesis in the central nervous system. Cell Mol. Life Sci. 2014, 71:3489-3506.
50. Verstappen C.C., Koeppen S., Heimans J.J., Huijgens P.C., Scheulen M.E., Strumberg D., Kiburg B., Postma T.J. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005, 64:1076-1077.
51. Wang F., Zhou F., Kruh G.D., Gallo J.M. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010, 12:1043-1049.
52. Yang Z.J., Ellis T., Markant S.L., Read T.A., Kessler J.D., Bourboulas M., Schuller U., Machold R., Fishell G., Rowitch D.H., et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008, 14:135-145.
53. Ye X., Wang Y., Cahill H., Yu M., Badea T.C., Smallwood P.M., Peachey N.S., Nathans J. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell 2009, 139:285-298.
54. Yuen T.J., Silbereis J.C., Griveau A., Chang S.M., Daneman R., Fancy S.P., Zahed H., Maltepe E., Rowitch D.H. Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angiogenesis. Cell 2014, 158:383-396.
55. Zhou Y., Wang Y., Tischfield M., Williams J., Smallwood P.M., Rattner A., Taketo M.M., Nathans J. Canonical WNT signaling components in vascular development and barrier formation. J. Clin. Invest. 2014, 124:3825-3846.